William Blair Reaffirms “Outperform” Rating for Glaukos (GKOS)
A number of other research analysts also recently issued reports on GKOS. Canaccord Genuity dropped their price objective on Glaukos from $48.00 to $43.00 and set a buy rating on the stock in a research note on Thursday. Stifel Nicolaus dropped their price objective on Glaukos from $42.00 to $39.00 and set a buy rating on the stock in a research note on Monday, February 26th. Cantor Fitzgerald set a $43.00 price objective on Glaukos and gave the company a buy rating in a research note on Wednesday. Zacks Investment Research downgraded Glaukos from a hold rating to a sell rating in a research note on Tuesday, February 13th. Finally, ValuEngine downgraded Glaukos from a hold rating to a sell rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Glaukos has a consensus rating of Buy and a consensus target price of $41.25.
Shares of Glaukos (GKOS) traded down $1.43 on Thursday, reaching $32.29. The company’s stock had a trading volume of 1,300,000 shares, compared to its average volume of 508,138. The firm has a market cap of $1,120.00 and a P/E ratio of 44.85. Glaukos has a 52-week low of $23.08 and a 52-week high of $52.48.
Institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its position in Glaukos by 93.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in Glaukos in the 3rd quarter valued at about $111,000. Quantbot Technologies LP increased its position in Glaukos by 291.3% in the 3rd quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock valued at $252,000 after buying an additional 5,697 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in Glaukos in the 2nd quarter valued at about $274,000. Finally, First Republic Investment Management Inc. increased its position in Glaukos by 47.1% in the 3rd quarter. First Republic Investment Management Inc. now owns 8,300 shares of the medical instruments supplier’s stock valued at $274,000 after buying an additional 2,659 shares in the last quarter.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.